Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation

MLA

Jing Sun, et al. “Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation.” Blood, vol. 122, Nov. 2013, p. 4637. EBSCOhost, https://doi.org/10.1182/blood.v122.21.4637.4637.

APA

Jing Sun, Hongsheng Zhou, Meiqing Wu, Qianli Jiang, Xinquan Liang, Min Dai, Xinmiao Jiang, Li Xuan, Na Xu, Fen Huang, Xiao-Jun Huang, Lan-Ping Xu, Zhiping Fang, Yu Zhang, Chaoyang Song, Dai-Hong Liu, Can Liu, & Qifa Liu. (2013). Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 122, 4637. https://doi.org/10.1182/blood.v122.21.4637.4637

Chicago

Jing Sun, Hongsheng Zhou, Meiqing Wu, Qianli Jiang, Xinquan Liang, Min Dai, Xinmiao Jiang, et al. 2013. “Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation.” Blood 122 (November): 4637. doi:10.1182/blood.v122.21.4637.4637.